Otonomy Inc (OTIC) |
|
2.63 0.04 (1.54%)
|
03-05 09:18 |
|
Open: |
2.58 |
Pre. Close: |
2.59 |
|
High:
|
2.69 |
Low:
|
2.42 |
|
Volume:
|
1,415,295 |
Market Cap:
|
127M |
|
|
|
|
Otonomy, Inc., a biopharmaceutical company, develops therapeutics for neurotology in the United States. The company offers OTIPRIO, a ciprofloxacin otic suspension for use during tympanostomy tube placement surgery in pediatric patients. It also develops OTIVIDEX, a sustained-exposure formulation of the steroid dexamethasone in Phase III clinical trial for the treatment of Ménière's disease; OTO-313, a sustained-exposure formulation of N-methyl-D-aspartate receptor antagonist gacyclidine, which is in Phase I/II clinical trial to treat tinnitus; and OTO-413, a sustained-exposure formulation of brain-derived neurotrophic factor that is in Phase I/II clinical trial for the repair of cochlear synaptopathy and the treatment of speech-in-noise hearing difficulties. In addition, the company develops OTO-510, an otoprotectant for the prevention of cisplatin-induced hearing loss; and OTO-6XX induces hair cell regeneration for the treatment of severe hearing loss. The company has license agreements with University of California and DURECT Corporation; and strategic collaboration with Applied Genetic Technologies Corporation to develop and commercialize gene therapy for congenital hearing loss. Otonomy, Inc. was founded in 2008 and is headquartered in San Diego, California. |
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
2.692 - 2.711 |
2.711 - 2.726 |
|
Low:
|
2.387 - 2.406 |
2.406 - 2.42 |
|
Close:
|
2.604 - 2.635 |
2.635 - 2.659 |
|
Technical analysis |
as of: 2021-03-05 8:50:45 AM |
|
Overall:
|
  |
| Stoxline posted a NEUTRAL today, upgraded from lower rating. Current trend continues, but could change at anytime. It is not a good time to buy or sell. |
| Target: |
Six months: 5.22  One year: 6.69 |
| Support: |
Support1: 2.42 Support2: 2.01 |
| Resistance: |
Resistance1: 4.47 Resistance2: 5.73 |
| Pivot: |
3.85 |
| Moving Average: |
MA(5): 2.78 MA(20): 4.24
MA(100): 4.63 MA(250): 3.72 |
| MACD: |
MACD(12,26): -0.67 Signal(9): -0.49 |
| Stochastic oscillator: |
%K(14,3): 6.61 %D(3): 8.51 |
| RSI: |
RSI(14): 26.82 |
| 52-week: |
High: 6.98 Low: 1.53 Change(%): -17.6 |
| Average Vol(K): |
3-Month: 118042 10-Days: 337818 |
|
Price, moving averages and Bollinger Bands |
|
Price and moving averages has closed below its Short term moving average. Short term moving average is currently below mid-term; AND below long term moving averages. From the relationship between price and moving averages; we can see that: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.OTIC has closed above bottom band by 25.2%. Bollinger Bands are 204.1% wider than normal. The large width of the bands suggest high volatility as compared to OTIC's normal range. The bands have been in this wide range for 8 bars. This is a sign that the current trend might continue. |
|
|
Headline News |
Fri, 26 Feb 2021
Are Options Traders Betting on a Big Move in Otonomy (OTIC) Stock? - Nasdaq
Wed, 24 Feb 2021
Otonomy Inc. (OTIC) Soars 2.08% on February 24 - Equities.com
Wed, 24 Feb 2021
What is the Market's View on Otonomy Inc (OTIC) Stock's Price and Volume Trends Wednesday? - InvestorsObserver
Mon, 22 Feb 2021
ROCE Insights For Otonomy - Benzinga
Mon, 22 Feb 2021
Otonomy Inc (OTIC) Down 52.50% in Premarket Trading - InvestorsObserver
Mon, 22 Feb 2021
Otonomy stock loses half its value after disappointing trial results of vertigo treatment - MarketWatch
|
Financial Analysis |
| Growth |
|
| Growth measures the growth of both a company's revenue and net income. it tells investors how fast a company is growing. |
| Profitability |
 |
| Profitability measures a company’s ability to generate earnings as compared to its expenses and other relevant costs. |
| Solvency |
|
| Solvency measures a company's ability to meet its long-term debts. Acceptable solvency ratios will vary from industry to industry. |
| Efficiency |
|
| Efficiency measures the strength of a company's return on invested capital. It can identify business that are better managed or not. |
| Price to Book Value: |
Outperform |
Discounted cash flow: |
Outperform |
| Return on Assets: |
Underperform |
Price to Earnings: |
Underperform |
| Return on Equity: |
Underperform |
Debt to Equity: |
Outperform |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NASDAQ |
| Sector: Healthcare |
| Industry: Biotechnology |
| Shares Out. (M) |
48 |
| Shares Float (M) |
38 |
|
% Held by Insiders
|
0.25 |
|
% Held by Institutions
|
77.21 |
|
Shares Short (K)
|
1,140 |
|
Shares Short P. Month (K)
|
1,110 |
Stock Financials |
|
EPS
|
-1.270 |
|
EPS Est This Year
|
-3.230 |
|
EPS Est Next Year
|
-2.310 |
|
Book Value (p.s.)
|
1.560 |
|
Profit Margin
|
|
|
Operating Margin
|
-14070.93 |
|
Return on Assets (ttm)
|
-26.5 |
|
Return on Equity (ttm)
|
-71.6 |
|
Qtrly Rev. Growth
|
-60.0 |
|
Gross Profit (p.s.)
|
-0.006 |
|
Sales Per Share
|
0.006 |
|
EBITDA (p.s.)
|
-0.889 |
|
Qtrly Earnings Growth
|
|
|
Operating Cash Flow (M)
|
-38 |
|
Levered Free Cash Flow (M)
|
-22 |
Stock Valuations |
|
PE Ratio
|
-2.07 |
|
PEG Ratio
|
|
|
Price to Book value
|
1.69 |
|
Price to Sales
|
405.26 |
|
Price to Cash Flow
|
-3.35 |
Stock Dividends |
|
Dividend
|
|
|
Forward Dividend
|
|
|
Dividend Yield
|
|
|
Dividend Pay Date
|
Invalid DateTime. |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
7 Binary Options
|
|
Your Ad Here
|
|
